StockDocs
Main Newswire Learn
Project by Matthew Castle Please send feedback to matthewgcastle@gmail.com
ALPS

Alps Group Inc

ALPS Nasdaq Services-Health Services EDGAR ↗
$0.40
+0.00 0.00%

Key statistics

from XBRL data in SEC filings
Market cap ⓘ
$66.6M
Revenue (TTM) ⓘ
—
Net income (TTM) ⓘ
—
EPS (TTM) ⓘ
—
P/E ratio ⓘ
—
Dividend yield ⓘ
—
Free cash flow ⓘ
—
Cash ⓘ
—
Total assets ⓘ
—
Gross margin ⓘ
—
52-week range ⓘ
$0.23 – $2.90

AI briefing

from the latest 10-K, 10-Q and 8-K events

Alps Group Inc is a health services company that filed its annual report on Form 20-F for the fiscal year ended March 31, 2026.

What they do

Alps Group Inc operates in the Services-Health Services industry, per its SIC classification. The company reports under IFRS and has a fiscal year ending March 31. Its filing shows property and equipment categories including medical equipment, laboratory equipment and laboratory space, computer and ICT equipment, renovation, aircraft, mobile devices, signboards, and motor vehicles.

Revenue drivers

  • Health services operations — The company is classified in Services-Health Services; the filing excerpts do not break out revenue by segment or product line.
  • Medical and laboratory equipment base — Property and equipment disclosures list medical equipment and laboratory equipment, implying in-house clinical or diagnostic capacity, but no related revenue figure is provided.

Recent performance

The 20-F covers the fiscal year ended March 31, 2026. The excerpts provided do not include income statement, revenue, or net income figures for the year. Balance sheet presentation shows ordinary shares, shares application money, merger reserves, fair value reserves, foreign currency basis spread reserves, retained earnings, equity attributable to owners of the parent, and noncontrolling interests for fiscal year ends 2023 through 2026. No numeric values for these line items are included in the excerpts.

Strategy

The filing excerpts indicate only limited strategic detail. A restructuring-related context is referenced with a date of March 31, 2027, suggesting a major restructuring announced or commenced. The company's equipment categories indicate continued investment across medical, laboratory, ICT and renovation assets. No further stated priorities, acquisitions, or capital plans are described in the provided material.

Risks

  • Limited disclosure in provided excerpts — The excerpts contain no revenue, margin, or cash flow figures, so financial performance cannot be assessed from this material.
  • Restructuring execution — A major restructuring is referenced with a March 31, 2027 date, which may affect operations and costs.
  • Foreign currency exposure — The equity presentation includes a reserve for change in value of foreign currency basis spreads, indicating exposure to currency movements.
  • Capital structure complexity — Equity includes ordinary shares, shares application money, merger reserves, and noncontrolling interests, all of which can affect per-share economics.

Outlook

The filing excerpts do not contain management's forward-looking outlook statement. The only forward-dated item is a reference to a major restructuring with a March 31, 2027 date. No revenue, earnings, or guidance figures are provided in the source material.